Evaluation of the effects of remdesivir and hydroxychloroquine on viral clearance in COVID-19: a randomized trial
…, M Haugli, R Eiken, AB Kildal… - Annals of internal …, 2021 - acpjournals.org
Background: New treatment modalities are urgently needed for patients with COVID-19. The
World Health Organization (WHO) Solidarity trial showed no effect of remdesivir or …
World Health Organization (WHO) Solidarity trial showed no effect of remdesivir or …
[HTML][HTML] Clinical characteristics, risk factors and outcomes in patients with severe COVID-19 registered in the International Severe Acute Respiratory and Emerging …
…, M Joseph, I Khan, ME Kho, AB Kildal… - ERJ open …, 2022 - Eur Respiratory Soc
Due to the large number of patients with severe coronavirus disease 2019 (COVID-19), many
were treated outside the traditional walls of the intensive care unit (ICU), and in many cases…
were treated outside the traditional walls of the intensive care unit (ICU), and in many cases…
Detailed stratified GWAS analysis for severe COVID-19 in four European populations
…, A Barreira, A Lleo, A Teles, AB Kildal… - Human molecular …, 2022 - academic.oup.com
Given the highly variable clinical phenotype of Coronavirus disease 2019 (COVID-19), a
deeper analysis of the host genetic contribution to severe COVID-19 is important to improve our …
deeper analysis of the host genetic contribution to severe COVID-19 is important to improve our …
What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? A harmonised, global longitudinal observational study protocol
Introduction Very little is known about possible clinical sequelae that may persist after
resolution of acute COVID-19. A recent longitudinal cohort from Italy including 143 patients …
resolution of acute COVID-19. A recent longitudinal cohort from Italy including 143 patients …
[HTML][HTML] Gut microbiota composition during hospitalization is associated with 60-day mortality after severe COVID-19
…, AM Dyrhol-Riise, AR Holten, K Tonby, AB Kildal… - Critical Care, 2023 - Springer
Background Gut microbiota alterations have been reported in hospitalized COVID-19 patients,
with reduced alpha diversity and altered microbiota composition related to respiratory …
with reduced alpha diversity and altered microbiota composition related to respiratory …
[HTML][HTML] Persistent pulmonary pathology after COVID-19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase-9
…, A Johannessen, R Hannula, S Aballi, AB Kildal… - Scientific Reports, 2021 - nature.com
The association between pulmonary sequelae and markers of disease severity, as well as
pro-fibrotic mediators, were studied in 108 patients 3 months after hospital admission for …
pro-fibrotic mediators, were studied in 108 patients 3 months after hospital admission for …
High circulating levels of the homeostatic chemokines CCL19 and CCL21 predict mortality and disease severity in COVID-19
A Tveita, SL Murphy, JC Holter, AB Kildal… - The Journal of …, 2022 - academic.oup.com
Background Immune dysregulation is a major factor in the development of severe coronavirus
disease 2019 (COVID-19). The homeostatic chemokines CCL19 and CCL21 have been …
disease 2019 (COVID-19). The homeostatic chemokines CCL19 and CCL21 have been …
Myosin activator omecamtiv mecarbil increases myocardial oxygen consumption and impairs cardiac efficiency mediated by resting myosin ATPase activity
JP Bakkehaug, AB Kildal, ET Engstad… - Circulation: Heart …, 2015 - Am Heart Assoc
Background— Omecamtiv mecarbil (OM) is a novel inotropic agent that prolongs systolic
ejection time and increases ejection fraction through myosin ATPase activation. We …
ejection time and increases ejection fraction through myosin ATPase activation. We …
[HTML][HTML] Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase …
…, JH Møller, BD Pollan, AA Tveita, AB Kildal… - Critical care, 2023 - Springer
Background Baricitinib has shown efficacy in hospitalized patients with COVID-19, but no
placebo-controlled trials have focused specifically on severe/critical COVID, including …
placebo-controlled trials have focused specifically on severe/critical COVID, including …
Respiratory dysfunction three months after severe COVID‐19 is associated with gut microbiota alterations
…, T Ranheim, AE Michelsen, AB Kildal… - Journal of Internal …, 2022 - Wiley Online Library
Background Although coronavirus disease 2019 (COVID‐19) is primarily a respiratory
infection, mounting evidence suggests that the gastrointestinal tract is involved in the disease, …
infection, mounting evidence suggests that the gastrointestinal tract is involved in the disease, …
